ICML 2023 | TEDDi-R regimen for secondary CNS lymphoma
Mark Roschewski
• 16 Jun 2023
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, briefly discusses a study evaluating the TEDDi-R regimen (ibrutinib, temozolomide, etoposide, liposomal doxorubicin, dexamethasone and rituximab) in patients with secondary CNS lymphoma (NCT03964090). Dr Roschewski comments on the rationale behind this regimen and summarizes the efficacy demonstrated so far. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
